Thank you very much.
Dr. Beeman, I'd like to go to you now, if I may. I've heard a lot of concerns from women's health groups in particular regarding carcinogenic agents. We've been talking about labelling. I know that some people have argued against mandatory labelling of toxic substances because it would impose prohibitive costs for little clear benefit. We've also heard the arguments that we don't need to put it into CEPA because of the “best-placed act” concept.
I just want to understand this from you: If we have these labelling requirements in other places, why are you suggesting that we have greater labelling requirements in CEPA? Do you think it would provide any additional benefits?